These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 32509577)
1. Clinical Significance of Hotspot Mutation Analysis of Urinary Cell-Free DNA in Urothelial Bladder Cancer. Hayashi Y; Fujita K; Matsuzaki K; Eich ML; Tomiyama E; Matsushita M; Koh Y; Nakano K; Wang C; Ishizuya Y; Kato T; Hatano K; Kawashima A; Ujike T; Uemura M; Imamura R; Netto GJ; Nonomura N Front Oncol; 2020; 10():755. PubMed ID: 32509577 [TBL] [Abstract][Full Text] [Related]
2. Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome. Allory Y; Beukers W; Sagrera A; Flández M; Marqués M; Márquez M; van der Keur KA; Dyrskjot L; Lurkin I; Vermeij M; Carrato A; Lloreta J; Lorente JA; Carrillo-de Santa Pau E; Masius RG; Kogevinas M; Steyerberg EW; van Tilborg AA; Abas C; Orntoft TF; Zuiverloon TC; Malats N; Zwarthoff EC; Real FX Eur Urol; 2014 Feb; 65(2):360-6. PubMed ID: 24018021 [TBL] [Abstract][Full Text] [Related]
3. Diagnostic potential of TERT promoter and FGFR3 mutations in urinary cell-free DNA in upper tract urothelial carcinoma. Hayashi Y; Fujita K; Matsuzaki K; Matsushita M; Kawamura N; Koh Y; Nakano K; Wang C; Ishizuya Y; Yamamoto Y; Jingushi K; Kato T; Kawashima A; Ujike T; Nagahara A; Uemura M; Imamura R; Takao T; Takada S; Netto GJ; Nonomura N Cancer Sci; 2019 May; 110(5):1771-1779. PubMed ID: 30887605 [TBL] [Abstract][Full Text] [Related]
4. Development of Sensitive Droplet Digital PCR Assays for Detecting Urinary Hosen MI; Forey N; Durand G; Voegele C; Bilici S; Avogbe PH; Delhomme TM; Foll M; Manel A; Vian E; Meziani S; De Tilly B; Polo G; Lole O; Francois P; Boureille A; Pisarev E; Salas AROSE; Monteiro-Reis S; Henrique R; Byrnes G; Jeronimo C; Scelo G; McKay JD; Calvez-Kelm FL; Zvereva M Cancers (Basel); 2020 Nov; 12(12):. PubMed ID: 33260905 [TBL] [Abstract][Full Text] [Related]
5. TERT promoter mutations and TERT mRNA but not FGFR3 mutations are urinary biomarkers in Han Chinese patients with urothelial bladder cancer. Wang K; Liu T; Liu C; Meng Y; Yuan X; Liu L; Ge N; Liu J; Wang C; Ren H; Yan K; Hu S; Xu Z; Fan Y; Xu D Oncologist; 2015 Mar; 20(3):263-9. PubMed ID: 25657201 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of TERT promoter mutations in urinary cell-free DNA and sediment DNA for detection of bladder cancer. Stasik S; Salomo K; Heberling U; Froehner M; Sommer U; Baretton GB; Ehninger G; Wirth MP; Thiede C; Fuessel S Clin Biochem; 2019 Feb; 64():60-63. PubMed ID: 30528938 [TBL] [Abstract][Full Text] [Related]
7. Toward urinary cell-free DNA-based treatment of urothelial carcinoma: a narrative review. Hayashi Y; Fujita K Transl Androl Urol; 2021 Apr; 10(4):1865-1877. PubMed ID: 33968675 [TBL] [Abstract][Full Text] [Related]
8. Urinary TERT promoter mutations as non-invasive biomarkers for the comprehensive detection of urothelial cancer. Avogbe PH; Manel A; Vian E; Durand G; Forey N; Voegele C; Zvereva M; Hosen MI; Meziani S; De Tilly B; Polo G; Lole O; Francois P; Delhomme TM; Carreira C; Monteiro-Reis S; Henrique R; Abedi-Ardekani B; Byrnes G; Foll M; Weiderpass E; McKay J; Jeronimo C; Scelo G; Le Calvez-Kelm F EBioMedicine; 2019 Jun; 44():431-438. PubMed ID: 31122840 [TBL] [Abstract][Full Text] [Related]
9. Toward Personalised Liquid Biopsies for Urothelial Carcinoma: Characterisation of ddPCR and Urinary cfDNA for the Detection of the Russo IJ; Ju Y; Gordon NS; Zeegers MP; Cheng KK; James ND; Bryan RT; Ward DG Bladder Cancer; 2018 Jan; 4(1):41-48. PubMed ID: 29430506 [TBL] [Abstract][Full Text] [Related]
10. Targeted deep sequencing of urothelial bladder cancers and associated urinary DNA: a 23-gene panel with utility for non-invasive diagnosis and risk stratification. Ward DG; Gordon NS; Boucher RH; Pirrie SJ; Baxter L; Ott S; Silcock L; Whalley CM; Stockton JD; Beggs AD; Griffiths M; Abbotts B; Ijakipour H; Latheef FN; Robinson RA; White AJ; James ND; Zeegers MP; Cheng KK; Bryan RT BJU Int; 2019 Sep; 124(3):532-544. PubMed ID: 31077629 [TBL] [Abstract][Full Text] [Related]
11. Urinary Exosomal and cell-free DNA Detects Somatic Mutation and Copy Number Alteration in Urothelial Carcinoma of Bladder. Lee DH; Yoon H; Park S; Kim JS; Ahn YH; Kwon K; Lee D; Kim KH Sci Rep; 2018 Oct; 8(1):14707. PubMed ID: 30279572 [TBL] [Abstract][Full Text] [Related]
12. TERT C228T mutation in non-malignant bladder urothelium is associated with intravesical recurrence for patients with non-muscle invasive bladder cancer. Hayashi Y; Fujita K; Nojima S; Tomiyama E; Matsushita M; Koh Y; Nakano K; Wang C; Ishizuya Y; Kato T; Hatano K; Kawashima A; Ujike T; Uemura M; Imamura R; Morii E; Nonomura N Mol Oncol; 2020 Oct; 14(10):2375-2383. PubMed ID: 32533903 [TBL] [Abstract][Full Text] [Related]
13. TERT Promoter Mutations as Simple and Non-Invasive Urinary Biomarkers for the Detection of Urothelial Bladder Cancer in a High-Risk Region. Pakmanesh H; Anvari O; Forey N; Weiderpass E; Malekpourafshar R; Iranpour M; Shahesmaeili A; Ahmadi N; Bazrafshan A; Zendehdel K; Kannengiesser C; Ba I; McKay J; Zvereva M; Hosen MI; Sheikh M; Calvez-Kelm FL Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430798 [TBL] [Abstract][Full Text] [Related]
14. Development of a Sensitive Digital Droplet PCR Screening Assay for the Detection of Jain M; Tivtikyan A; Kamalov D; Avdonin S; Rakhmatullin T; Pisarev E; Zvereva M; Samokhodskaya L; Kamalov A Biomedicines; 2023 Feb; 11(2):. PubMed ID: 36831030 [TBL] [Abstract][Full Text] [Related]
15. Non-invasive prediction of recurrence in bladder cancer by detecting somatic TERT promoter mutations in urine. Descotes F; Kara N; Decaussin-Petrucci M; Piaton E; Geiguer F; Rodriguez-Lafrasse C; Terrier JE; Lopez J; Ruffion A Br J Cancer; 2017 Aug; 117(4):583-587. PubMed ID: 28683471 [TBL] [Abstract][Full Text] [Related]
16. Muralidharan K; Yekula A; Small JL; Rosh ZS; Kang KM; Wang L; Lau S; Zhang H; Lee H; Bettegowda C; Chicoine MR; Kalkanis SN; Shankar GM; Nahed BV; Curry WT; Jones PS; Cahill DP; Balaj L; Carter BS Clin Cancer Res; 2021 Jan; 27(1):169-178. PubMed ID: 33051308 [TBL] [Abstract][Full Text] [Related]
17. TERT Promoter Mutation in Serum Cell-Free DNA Is a Diagnostic Marker of Primary Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease. Akuta N; Kawamura Y; Kobayashi M; Arase Y; Saitoh S; Fujiyama S; Sezaki H; Hosaka T; Kobayashi M; Suzuki Y; Suzuki F; Ikeda K; Kumada H Oncology; 2021; 99(2):114-123. PubMed ID: 32998139 [TBL] [Abstract][Full Text] [Related]
18. Urinary UBC Rapid and NMP22 Test for Bladder Cancer Surveillance in Comparison to Urinary Cytology: Results from a Prospective Single-Center Study. Pichler R; Tulchiner G; Fritz J; Schaefer G; Horninger W; Heidegger I Int J Med Sci; 2017; 14(9):811-819. PubMed ID: 28824318 [No Abstract] [Full Text] [Related]
19. Urinary Molecular Pathology for Patients with Newly Diagnosed Urothelial Bladder Cancer. Zhang R; Zang J; Xie F; Zhang Y; Wang Y; Jing Y; Zhang Y; Chen Z; Shahatiaili A; Cai MC; Zhao Z; Du P; Jia S; Zhuang G; Chen H J Urol; 2021 Oct; 206(4):873-884. PubMed ID: 34061567 [TBL] [Abstract][Full Text] [Related]
20. Detection of TERT promoter mutation in serum cell-free DNA using wild-type blocking PCR combined with Sanger sequencing in hepatocellular carcinoma. Akuta N; Suzuki F; Kobayashi M; Fujiyama S; Kawamura Y; Sezaki H; Hosaka T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Suzuki Y; Kumada H J Med Virol; 2020 Dec; 92(12):3604-3608. PubMed ID: 32100879 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]